Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Clinical Endocrinology|April 28, 2011
Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidismKarin Frank-Raue, Gudrun Leidig-Bruckner, Christine Haag, et al.
Plos One|December 16, 2014
Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemiaSaskia Letz, Christine Haag, Egbert Schulze, et al.
European Journal of Endocrinology|June 12, 2004
Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor geneKarin Frank-Raue, Angela Lorenz, Christine Haag, et al.
The Journal of Clinical Endocrinology and Metabolism|February 20, 2020
Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic MorphologyTheresa Vogel, Julia Wendler, Karin Frank-Raue, et al.
Thyroid : Official Journal of the American Thyroid Association|August 13, 2020
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid CancerViktoria F Koehler, Pia Adam, Karin Frank-Raue, et al.
The Journal of Clinical Endocrinology and Metabolism|September 18, 2008
Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptorsRamona Rus, Christine Haag, Christiane Bumke-Vogt, et al.
Clinical Endocrinology|June 26, 2007
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriersAndreas Machens, Ludwig Schaaf, Wolfram Karges, et al.
The Journal of Clinical Endocrinology and Metabolism|July 30, 2010
Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptorsSaskia Letz, Ramona Rus, Christine Haag, et al.
Thyroid : Official Journal of the American Thyroid Association|September 6, 2012
Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinomaKarin Frank-Raue, Andreas Machens, Gudrun Leidig-Bruckner, et al.
European Journal of Endocrinology|March 7, 2008
Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinomaMario Colombo-Benkmann, Zhenpeng Li, Burkhard Riemann, et al.
Pageof 7